Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Anticancer Therapies Congress 2027

The ESMO TAT Congress 2027 is a leading international meeting for early‑phase clinical development and translational research in targeted therapies. The ESMO TAT Congress 2027 is a leading international meeting for early‑phase clinical development...

PHC Launched MTR-OPC1-PW Interface Board in September to Strengthen Data Linkage Between Equipment and Customer Systems

PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; Head Office: Chiyoda-ku, Tokyo; President: Shinro Nakamura; hereinafter referred to as "PHC") Life Science Division Biomedica Business Group (PHCbi) is pleased to announce that the MTR-OPC-OPC1-PW,...

Avenacy Launched Cyclophosphamide for Injection, USP in the U.S. Market

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced it has launched Cyclophosphamide for Injection, USP in the United States as a therapeutic generic equivalent for Cytoxan® as approved by...

5th MENA Congress for Rare Diseases 2026

5th MENA Congress for Rare Diseases 2026 will take place from 3 to 5 September 2026 at Beach Rotana Hotel, Abu Dhabi, United Arab Emirates. 5th MENA Congress for Rare Diseases 2026 will take place from 3 to 5 September 2026 at Beach Rotana Hotel,...

New HCPCS Billing Code Enables Medicare Reimbursement for Lasix® ONYU When Furnished Incident to a Physician’s Service

SQ Innovation announced that the Centers for Medicare & Medicaid Services (CMS) has established a new Healthcare Common Procedure Coding System (HCPCS) Level II code, J1946 ("Injection, furosemide (Lasix ONYU), 1 mg"), for its product Lasix® ONYU...

Karyopharm Files Supplemental New Drug Application with FDA for XPOVIO® (Selinexor) in Combination with Ruxolitinib for the Treatment of Myelofibrosis

Karyopharm Therapeutics Inc. a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking Accelerated...

U.S. FDA Approves Ziihera® (zanidatamab-hrii), With or Without Tislelizumab Plus Chemotherapy, for the First-Line Treatment of HER2-Positive Advanced Gastroesophageal Adenocarcinoma

Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) approved two Ziihera® (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive...

Upsher-Smith Expands Neurology Portfolio with the Launch of Glatiramer Acetate Injection

Upsher-Smith Laboratories, LLC a subsidiary of Bora Pharmaceuticals Co., Ltd. (6472.TW and BORAY.OTCQX), announced the recent launch of Glatiramer Acetate Injection in 20 mg/mL and 40 mg/mL strengths, adding to the Company's portfolio of complex...

Dunbar Pharma Brings First Plant-Derived Dronabinol API to the UK Market Through IPS Pharma

Dunbar Pharmaceuticals Ireland's first EU GMP-certified manufacturer of plant-derived cannabinoid active pharmaceutical ingredients (APIs), announced that its plant-derived dronabinol API, WaterClear THC™, is now available across the United...

PanTRKare™ Is Officially Approved as the Companion Diagnostic for VELMARTO® (Eratrectinib)

NMPA granted approval to Geneseeq's PanTRKare™ NTRK1/2/3 Gene Fusion Detection Kit as a companion diagnostic for VELMARTO® (Eratrectinib), a next‑generation highly selective TRK inhibitor independently developed by Vcare PharmaTech. The approval...

Neurolief Advances Veteran Mental Health and Migraine Care With New VA Contract for Prescription Neuromodulation

Neurolief, a neuroscience-driven medical technology company developing brain neuromodulation therapies for mental health and neurological conditions, is bringing two prescription therapies to U.S. veterans through a new Department of Veterans...

Takeda's ORZEYFUL™ Receives U.S. FDA Approval for Narcolepsy Type 1

Takeda announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent...

US Capital Global Securities Announces $20 Million Offering for Thplasma to Invest in the Future of Plasma Therapeutics

US Capital Global Securities LLC, the SEC-registered broker-dealer affiliate of the global financial group US Capital Global, is pleased to present eligible investors with the opportunity to participate in a $20 million financing for Thplasma...

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection in two single-dose vial strengths

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch1 of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to...

EMS and BD expand access to GLP-1 therapies in Brazil by launching semaglutide.

BD a leading global medical technology company, and EMS, one of Brazil's leading pharmaceutical companies, announced their collaboration in the launch of a semaglutide therapy in Brazil. This collaboration and launch underscore a shared commitment...

InstaMed® Pharmaceuticals Appoints Tracy Gibbs, PhD, as Chief Executive Officer Ahead of the Worldwide Launch of Its Non-Injectable Peptide Platform

InstaMed® Pharmaceuticals, an advanced biotechnology company transforming peptide delivery through its patented InstaRelease® oral dissolving strip platform, announced the appointment of Tracy Gibbs, PhD, as Chief Executive Officer. The leadership...

FDA Clears Roche's cobas® BV/CV Assay, Enabling Fast and Highly Accurate Diagnosis of Vaginitis

Roche announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its cobas® BV/CV (Bacterial vaginosis/Candida vaginitis) assay. This molecular diagnostic test provides results for both Bacterial vaginosis (BV) and...

China Approves Haisco's Class 1 Innovative Drug, Ciprocopan Succinate Tablets, Providing a New Treatment Option for Patients with PNH

Haisco Pharmaceutical Group claimed today their independently developed Class 1 innovative drug, Ciprocopan Succinate Tablets (development code: HSK39297), has received marketing approval from the National Medical Products Administration of China...

Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX Approved by the European Commission as a First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

Merck, a leading global science and technology company, announced that the European Commission (EC) approved an update to the Erbitux (cetuximab) EU label on June 26, 2026. Erbitux is now indicated in combination with encorafenib for patients with...

BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia Accepted by the U.S. Food and Drug Administration

BioMarin Pharmaceutical Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) for VOXZOGO® (vosoritide) for full approval in children with achondroplasia. . "This...